Answers are grounded in this paper and cite their sources.
Migraine headaches are a very common complaint described by patients and few medications have been designed solely for their treatment. Current knowledge of migraine pathogenesis relates to various neuropeptides, including calcitonin gene related peptide (CGRP), acting on blood vessels within the brain and causing vasodilation. Sensory fibers detect this change and it is perceived as pain. This understanding has led to the development of CGRP monoclonal antibodies as possible migraine treatment. Concern that arises with this new migraine medication, are the cardiovascular side effects.
No takes yet. Share an insight, caveat, or question.
Kimberly et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: